Legal Representation
Attorney
Lisa M. Tittemore
USPTO Deadlines
Next Deadline
180 days remaining
Statement of Use Due - Extension 4 Granted
Due Date
January 25, 2026
Extension Available
Until July 25, 2024
Application History
41 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 22, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 21, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jul 21, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jul 21, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 6, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 6, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jun 6, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Mar 4, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 25, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jan 24, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 24, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 24, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 18, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 18, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jul 18, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jun 26, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 26, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jun 26, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jun 26, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 26, 2024 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Jun 26, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jan 24, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 22, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 22, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jan 22, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jul 25, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 30, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 30, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 10, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 22, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 12, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 11, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 11, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 21, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 11, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 11, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 11, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 11, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 11, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jan 10, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 8, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and medical preparations for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; Pharmaceutical therapeutics for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases
Class 042
Research and development of therapeutic drugs for the treatment of cancer, immune inflammatory diseases, and autoimmune diseases; Research and development of therapeutic antibodies and pharmaceuticals; Research and development of technology in the field of therapeutic antibodies, pharmaceuticals and biopharmaceuticals; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services and drug discovery services; Medical research for development of therapeutic modalities for treatment of diseases; Custom design and development of biochemical assays and chemical reagents for use in scientific and biomedical research; Clinical studies, namely, clinical research in the field of oncology, immune oncology, and autoimmune diseases; Preclinical and clinical development of therapeutic products being pharmaceutical preparations and medicines
Additional Information
Design Mark
The mark consists of two four-sided polygons above a downward-facing letter "K", where the two polygons form the eyes of an animal's face and the letter "K" forms the nose and mouth of an animal's face.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042